The global acute respiratory distress syndrome therapeutics market is anticipated to grow at a considerable CAGR of 7.2% during the forecast period (2023-2029). A number of government information initiatives are underway to educate the public about the various diagnoses and treatments accessible. Several items with superior powers have been launched by major market businesses. Hospitals/Clinics are well equipped with advanced technological equipment for surgical procedures and improved treatments and the hospital segment is witnessing rapid growth, owing to the growing number of hospital admission with the ARDS therapeutics, the increasing number of patient pools, and the launch of new products by the market players are expected to continue over the forecast period, and thus, driving growth in the segment.
The increasing number of hospitals by private players is also expected to propel the growth of the market. For instance, in April 2022, the Food and Drug Administration (FDA) approved Direct Biologics to proceed with a Landmark Phase 3 clinical trial using its investigation EV Drug ExoFlow to treat acute respiratory distress syndrome (ARDS) therapeutic. For instance, in January 2022, Veru declared that Sabizabulin has been given a fast-track designation by the FDA for the treatment of hospitalized COVID-19 patients who are at high risk of developing acute respiratory distress syndrome.
To Request a Sample of our Report on Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market: https://www.omrglobal.com/request-sample/acute-respiratory-distress-syndrome-ards-therapeutics-market
Market Coverage
- The market number available for – 2023-2029
- Base year- 2022
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Drug Class
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Therabron Therapeutics, Inc, Serendex Pharmaceuticals A/S, Silence Therapeutics Plc, Histocell S.L., Altor BioScience Corporation, and others.
Acute Respiratory Distress Syndrome Therapeutics Market Report Segment
By Type
- Methylprednisolone
- Hydrocortisone
- Calf Pulmonary Surfactant for Injection
- Others
By Drug Class
- Corticosteroids
- Antimicrobials
- Bronchodilators
- Other Medications
By Application
- In-Patient
- Out-Patient
A full Report of Acute Respiratory Distress Syndrome (ARDS) Therapeutics Marketis Available @ https://www.omrglobal.com/industry-reports/acute-respiratory-distress-syndrome-ards-therapeutics-market
Acute respiratory distress syndrome therapeutics Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- Altor BioScience Corp.
- Athersys, Inc
- Faron Pharmaceuticals Oy
- FirstString Research, Inc.
- FRESENIUS SE & CO. KGAA
- GETINGE AB
- GILEAD SCIENCES INC.
- GlaxoSmithKline Plc
- Histocell S.L.
- Medtronic, Inc.
- NIPRO and PFIZER INC.
- Phylogica Ltd.
- Serendex Pharmaceuticals A/S
- Silence Therapeutics plc
- Terumo Corp.
- Therabron Therapeutics, Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/acute-respiratory-distress-syndrome-ards-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
